Results of Wave’s huntingtin lowering trial explained – video!

Just before the new year, Wave Life Sciences announced that the drug in their huntingtin lowering trial, PRECISION-HD2, had successfully lowered the concentration of mutant huntingtin protein, while healthy huntingtin was left unchanged. Video below! Why is this so exciting? To put it simply: if you inherit Huntington’s disease, you have one sick gene and one healthy gene. Both genes code for a […]

Unpacking Wave’s PRECISION-HD2 huntingtin-lowering trial announcement

Left to right: Anne Lennon Bird, Svein Olaf Olsen and Astri Arnesen.

Just before the new year, Wave announced that the drug in the PRECISION-HD2 trial had successfully lowered the concentration of mutant huntingtin in the spinal fluid. By Dr Jeff Carroll | Edited by Dr Ed WildPublished January 03, 2020 at DNA-based drugs called antisense oligonucleotides, or ASOs, are now in multiple clinical trials in Huntington’s disease, aiming to lower production […]

2019 ends with exciting results from Wave PRECISION-HD2 trial!

Today, December 30, Wave announced the first preliminary results from the their study PRECISION-HD2 . So far the results are very exciting and promising. It’s very encouraging to enter a new year with such exciting news from Wave. I look forward with optimism to the next steps in these trials. Astri Arnesen, President EHA In PRECISION-HD2 […]

Precision HD trial update

The exciting trials Precision HD 1 and 2, continue to enroll participants. Wave Life Sciences expect to share the first results by the end of 2019. In the Huntingtin lowering trials, Wave Life Sciences only target the mutant Huntingtin protein. This is a completely unique approach.  Learn more: New Treatment? The initial timelines have been delayed by […]